Medigen Biotechnology (3176) - Net Assets
Based on the latest financial reports, Medigen Biotechnology (3176) has net assets worth NT$4.90 Billion TWD (≈ $154.29 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$6.34 Billion ≈ $199.85 Million USD) and total liabilities (NT$1.45 Billion ≈ $45.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medigen Biotechnology liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$4.90 Billion |
| % of Total Assets | 77.21% |
| Annual Growth Rate | 8.8% |
| 5-Year Change | 11.97% |
| 10-Year Change | 45.43% |
| Growth Volatility | 34.41 |
Medigen Biotechnology - Net Assets Trend (2003–2024)
This chart illustrates how Medigen Biotechnology's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Medigen Biotechnology for the complete picture of this company's asset base.
Annual Net Assets for Medigen Biotechnology (2003–2024)
The table below shows the annual net assets of Medigen Biotechnology from 2003 to 2024. For live valuation and market cap data, see 3176 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.04 Billion ≈ $158.73 Million |
+0.82% |
| 2023-12-31 | NT$5.00 Billion ≈ $157.44 Million |
-22.78% |
| 2022-12-31 | NT$6.47 Billion ≈ $203.87 Million |
+0.70% |
| 2021-12-31 | NT$6.43 Billion ≈ $202.46 Million |
+42.82% |
| 2020-12-31 | NT$4.50 Billion ≈ $141.76 Million |
+67.56% |
| 2019-12-31 | NT$2.69 Billion ≈ $84.60 Million |
-8.70% |
| 2018-12-31 | NT$2.94 Billion ≈ $92.66 Million |
-7.52% |
| 2017-12-31 | NT$3.18 Billion ≈ $100.19 Million |
-10.10% |
| 2016-12-31 | NT$3.54 Billion ≈ $111.46 Million |
+2.12% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.14 Million |
-5.32% |
| 2014-12-31 | NT$3.66 Billion ≈ $115.28 Million |
+19.28% |
| 2013-12-31 | NT$3.07 Billion ≈ $96.64 Million |
+49.34% |
| 2012-12-31 | NT$2.05 Billion ≈ $64.71 Million |
+124.29% |
| 2011-12-31 | NT$915.79 Million ≈ $28.85 Million |
+13.35% |
| 2010-12-31 | NT$807.90 Million ≈ $25.45 Million |
+35.32% |
| 2009-12-31 | NT$597.02 Million ≈ $18.81 Million |
+10.63% |
| 2008-12-31 | NT$539.65 Million ≈ $17.00 Million |
+15.14% |
| 2007-12-31 | NT$468.68 Million ≈ $14.77 Million |
-29.83% |
| 2006-12-31 | NT$667.93 Million ≈ $21.04 Million |
+2.70% |
| 2005-12-31 | NT$650.39 Million ≈ $20.49 Million |
-12.02% |
| 2004-12-31 | NT$739.26 Million ≈ $23.29 Million |
-13.70% |
| 2003-12-31 | NT$856.65 Million ≈ $26.99 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medigen Biotechnology's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35266200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$1.93 Billion | 122.29% |
| Total Equity | NT$1.58 Billion | 100.00% |
Medigen Biotechnology Competitors by Market Cap
The table below lists competitors of Medigen Biotechnology ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NCC AB (publ)
ST:NCC-A
|
$144.84 Million |
|
Domo Inc
NASDAQ:DOMO
|
$144.89 Million |
|
Heran Co Ltd
TW:5283
|
$144.89 Million |
|
NevGold Corp
V:NAU
|
$144.97 Million |
|
Insas Bhd
KLSE:3379
|
$144.61 Million |
|
Carbios
PA:ALCRB
|
$144.57 Million |
|
PRL Global Ltd
AU:PRG
|
$144.53 Million |
|
INKEVERSE GROUP DL-001
F:5IK
|
$144.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medigen Biotechnology's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,591,643,000 to 1,581,890,000, a change of -9,753,000 (-0.6%).
- Net loss of 204,690,000 reduced equity.
- Dividend payments of 54,190,000 reduced retained earnings.
- New share issuances of 3,403,000 increased equity.
- Other comprehensive income decreased equity by 11,349,000.
- Other factors increased equity by 257,073,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-204.69 Million | -12.94% |
| Dividends Paid | NT$54.19 Million | -3.43% |
| Share Issuances | NT$3.40 Million | +0.22% |
| Other Comprehensive Income | NT$-11.35 Million | -0.72% |
| Other Changes | NT$257.07 Million | +16.25% |
| Total Change | NT$- | -0.61% |
Book Value vs Market Value Analysis
This analysis compares Medigen Biotechnology's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.08x to 2.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | NT$15.87 | NT$32.95 | x |
| 2017-12-31 | NT$13.25 | NT$32.95 | x |
| 2018-12-31 | NT$11.08 | NT$32.95 | x |
| 2019-12-31 | NT$9.81 | NT$32.95 | x |
| 2020-12-31 | NT$13.06 | NT$32.95 | x |
| 2021-12-31 | NT$17.23 | NT$32.95 | x |
| 2022-12-31 | NT$15.77 | NT$32.95 | x |
| 2023-12-31 | NT$11.42 | NT$32.95 | x |
| 2024-12-31 | NT$11.36 | NT$32.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medigen Biotechnology utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.91%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 4.24x
- Recent ROE (-12.94%) is below the historical average (-11.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 41.35% | 2221.02% | 0.01x | 1.31x | NT$141.96 Million |
| 2008 | 8.63% | 113.36% | 0.06x | 1.33x | NT$-6.99 Million |
| 2012 | 20.91% | 378.54% | 0.05x | 1.13x | NT$217.27 Million |
| 2015 | -21.69% | -149.01% | 0.08x | 1.80x | NT$-790.34 Million |
| 2016 | -25.82% | -142.12% | 0.08x | 2.19x | NT$-788.45 Million |
| 2017 | -25.40% | -109.19% | 0.09x | 2.65x | NT$-650.49 Million |
| 2018 | -28.80% | -108.68% | 0.09x | 2.99x | NT$-596.40 Million |
| 2019 | -18.79% | -46.30% | 0.11x | 3.55x | NT$-391.83 Million |
| 2020 | -18.61% | -55.02% | 0.10x | 3.39x | NT$-519.46 Million |
| 2021 | -2.20% | -1.34% | 0.48x | 3.42x | NT$-292.05 Million |
| 2022 | -30.81% | -64.01% | 0.11x | 4.55x | NT$-895.28 Million |
| 2023 | -35.27% | -48.48% | 0.14x | 5.36x | NT$-720.46 Million |
| 2024 | -12.94% | -14.91% | 0.20x | 4.24x | NT$-362.88 Million |
Industry Comparison
This section compares Medigen Biotechnology's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,587,665,111
- Average return on equity (ROE) among peers: 5.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medigen Biotechnology (3176) | NT$4.90 Billion | 41.35% | 0.30x | $144.62 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more